RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Service Contact Center

Contact details for order support and technical support.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

Service Contact Center

Contact details for order support and technical support.

Learning Hub

Explore resources, including product documentation, software, webinars, videos, virtual demos and more.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

Quality & Safety Data

Find quality and safety documentation for your products.

Product & Technical Support

Find out which products work together, search our FAQ database and troubleshoot.

Ordering from QIAGEN

Learn about easy ordering options that offer fast and reliable delivery.

Directors Dealings

Home  >  Investor Relations  >  Financial Reports & SEC Filings  >  Directors Dealings

QIAGEN publishes information on directors' dealings as reported to the company and pursuant to regulations by the United States Securities and Exchange Commission (SEC) and the Netherlands Authority for the Financial Markets (A-FM) pursuant to Section 2a Wmz 1996 and Art. 19. EU Directive No. 596/2014. Our insider trading policy can be downloaded as PDF document here.

Notes to the overview of recent transactions

* Cashless Exercise

1) According to a Rule 10b5-1 long-term Sales Plan ("Langzeitverkaufsvertrag").

2) Lawrence A. Rosen, Stéphane Bancel, Metin Colpan, Thomas Ebeling, Toralf Haag, Ross L. Levine, Elaine R. Mardis, Lawrence A. Rosen, Elizabeth E. Tallett.

“Net share settlement” is done when a number of shares to cover expenses related to the grant release (such as taxes and transaction costs) are withheld by the Company.

Recent transactions

Name and function Date and type Financial instrument Amount of shares SEC BAFin A-FM
Elaine Mardis,
Supervisory Director
03/17/21 Common Shares 4,909 PDF PDF PDF
Stéphane Bancel,
Supervisory Director
03/02/21 Common Shares 4,968 PDF PDF PDF
Lawrence A. Rosen,
Supervisory Director
03/01/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 3,326 - PDF PDF
Stéphane Bancel,
Supervisory Director
03/01/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 3,037 - PDF PDF
Metin Colpan,
Supervisory Director
03/01/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 3,238 - PDF PDF
Elaine R. Mardis,
Supervisory Director
03/01/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 3,008 - PDF PDF
Elizabeth E. Tallett,
Supervisory Director
03/01/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 3,326 - PDF PDF
Thierry Bernard,
Managing Director
03/01/21 Common Shares received through release of Performance Stock Units ("net share settlement") 2,477 - PDF PDF
Roland Sackers,
Managing Director
03/01/21 Common Shares received through release of Performance Stock Units ("net share settlement") 12,430 - PDF PDF
Lawrence A. Rosen,
Supervisory Director
02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 2,095 - PDF PDF
Stéphane Bancel,
Supervisory Director
02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 1,931 - PDF PDF
Metin Colpan,
Supervisory Director
02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 2,217 - PDF PDF
Ross L. Levine,
Supervisory Director
02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 1,978 - PDF PDF
Elaine R. Mardis,
Supervisory Director
02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 1,901 - PDF PDF
Elizabeth E. Tallett,
Supervisory Director
02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 2,095 - PDF PDF
Roland Sackers,
Managing Director
02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 6,923 - PDF PDF
All Supervisory
Board Directors2)
02/26/21 Grant Restricted Stock Units 7,482 - PDF PDF
Roland Sackers,
Managing Director
02/26/21 Common Shares received through release of Performance Stock Units ("net share settlement") 5,594 - PDF PDF
Thierry Bernard,
Managing Director
02/21/21 Common Shares received through release of Performance Stock Units ("net share settlement") 10,371 - PDF PDF
Roland Sackers,
Managing Director
02/21/21 Common Shares received through release of Performance Stock Units ("net share settlement") 21,467 - PDF PDF
Metin Colpan,
Supervisory Director
02/16/21-02/17/21 Common Shares 770,370 - PDF PDF
Thierry Bernard,
Managing Director
02/15/21 Common Shares received through release of Performance Stock Units ("net share settlement") 23,410 - PDF PDF
Metin Colpan,
Supervisory Director
12/15/20-12/17/20 Common Shares 2,383,686 PDF PDF
Elaine R. Mardis,
Supervisory Director
09/09/20-09/11/20 Common Shares 5,956 PDF PDF PDF
Roland Sackers,
Managing Director
08/26/20
Purchase
Common Shares 8,573 - PDF PDF
Thierry Bernard, CEO 04/23/20 Common Shares 9,500 PDF PDF PDF
Roland Sackers,
Managing Director
04/23/20 Common Shares 25,177 PDF PDF PDF
Metin Colpan,
Supervisory Director
04/20/20 Sale* Stock Option Exercise
(Expiry: February 2021 and March 22)
4,567 PDF PDF PDF
Roland Sackers,
Managing Director
04/20/20-04/21/20
Sale*
Stock Option Exercise
(Expiry: March 2022 and February 2023)
58,360 PDF PDF PDF
Roland Sackers,
Managing Director
03/20/20 Sale*a) Stock Option Exercise
(Expiry: February 2021)
77,379 PDF PDF PDF